UNSPSC 51124102: Adenosine diphosphate

This classification denotes a nucleoside C10H15N5O10P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 61D2G4IYVH, chemically known as adenosine, 5'-(trihydrogen pyrophosphate), but more generally known as adenosine diphosphate, which bears US NIH Compound Identifier 6022. European Medicines Agency schedules Adenosine diphosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12740MIG. Most nations, for tariff and trade purposes, schedule adenosine diphosphate under HS 29349990 and SITC 51579.

As of Q4 2014, ADENOSINE DIPHOSPHATE remains US FDA's Preferred Term for this commodity. SMILES: C1NC(C2C(N1)N(CN2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)OP(=O)(O)O)O)O)N.

UNSPSC 51124102 Adenosine diphosphate is a Commodity code covering injectable medications used in emergency medical response and acute care settings, specifically adenosine formulations deployed by fire rescue departments and hospital systems. State and local governments procure this medication primarily through fire departments, emergency medical services, health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves supplying pharmaceutical products with strict expiration-date requirements, temperature stability guarantees, and compliance with federal hazard communication and drug supply chain security standards. Vendors must typically warrant product integrity for a minimum of 365 days, arrange for pickup and replacement of expired stock, and demonstrate Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance.

Recent activity concentrates in Florida and Minnesota, with the City of Tampa Fire Rescue issuing an IFB (solicitation 26P00188, due April 8, 2026) for advanced life support medications including 330 units of adenosine 6mg vials as part of a four-item drug bundle with an estimated contract value of $40,000.00 and a one-year term with two optional renewals. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and pricing weighted 75 percent on competitiveness with a two-year initial term. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) in early April 2026 exploring direct-to-manufacturer prescription programs, signaling exploratory procurement strategy development in the state pharmaceutical supply space.